Wall Street Analysts See a 279% Upside in MacroGenics (MGNX): Can the Stock Really Move This High?Zacks Investment Research • 11/01/22
MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference CallGlobeNewsWire • 10/26/22
MacroGenics (MGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/25/22
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific AntibodiesBusiness Wire • 10/17/22
Wall Street Analysts Predict a 291% Upside in MacroGenics (MGNX): Here's What You Should KnowZacks Investment Research • 08/12/22
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q2 2022 Results Earnings Call TranscriptSeeking Alpha • 08/09/22
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/08/22
MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference CallGlobeNewsWire • 07/25/22
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck CancerGlobeNewsWire • 07/08/22
MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/04/22
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial ResultsGlobeNewsWire • 05/03/22
MacroGenics Announces Date of First Quarter 2022 Financial Results Conference CallGlobeNewsWire • 04/25/22
MacroGenics, Inc. (MGNX) CEO Scott Canning on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/25/22
MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference CallGlobeNewsWire • 02/14/22